[go: up one dir, main page]

MX2010005324A - Composiciones y metodos para inhibir el avance del tumor. - Google Patents

Composiciones y metodos para inhibir el avance del tumor.

Info

Publication number
MX2010005324A
MX2010005324A MX2010005324A MX2010005324A MX2010005324A MX 2010005324 A MX2010005324 A MX 2010005324A MX 2010005324 A MX2010005324 A MX 2010005324A MX 2010005324 A MX2010005324 A MX 2010005324A MX 2010005324 A MX2010005324 A MX 2010005324A
Authority
MX
Mexico
Prior art keywords
methods
compositions
tumor progression
inhibiting tumor
emt
Prior art date
Application number
MX2010005324A
Other languages
English (en)
Inventor
Victoria Smith
Jo-Anne S Hongo
Jing Li
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2010005324A publication Critical patent/MX2010005324A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proveen composiciones y métodos para la clasificación, diagnosis, tratamiento y prevención de tumores caracterizados por la pérdida de función de REST, expresión de ß2 y/o activación de Notch. Se proveen composiciones y métodos adicionales para modulación de procesos celulares tales como EMT, migración celular y apóptosis.
MX2010005324A 2007-11-19 2008-11-18 Composiciones y metodos para inhibir el avance del tumor. MX2010005324A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98887407P 2007-11-19 2007-11-19
PCT/US2008/083865 WO2009067429A1 (en) 2007-11-19 2008-11-18 Compositions and methods for inhibiting tumor progression

Publications (1)

Publication Number Publication Date
MX2010005324A true MX2010005324A (es) 2010-06-01

Family

ID=40336462

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005324A MX2010005324A (es) 2007-11-19 2008-11-18 Composiciones y metodos para inhibir el avance del tumor.

Country Status (11)

Country Link
US (1) US8563695B2 (es)
EP (1) EP2220123A1 (es)
JP (2) JP5745272B2 (es)
KR (1) KR20100087330A (es)
CN (1) CN101932605B (es)
AU (1) AU2008326497B2 (es)
BR (1) BRPI0817393A2 (es)
CA (1) CA2702462A1 (es)
IL (1) IL204945A0 (es)
MX (1) MX2010005324A (es)
WO (1) WO2009067429A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563695B2 (en) * 2007-11-19 2013-10-22 Genentech, Inc. Antibodies that bind β2
US9618514B2 (en) 2012-09-17 2017-04-11 Agios Pharmaceuticals, Inc Methods of evaluating patients using E-cadherin and vimentin
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
AU2015231053B2 (en) 2014-03-21 2019-04-11 Les Laboratoires Servier Compounds and their methods of use
WO2016089928A1 (en) * 2014-12-01 2016-06-09 Weitz Andrew C Methods for treating and assessing tumor invasion and metastasis
CN106749617A (zh) * 2016-12-01 2017-05-31 南方医科大学 一种人notch1 nicd蛋白抗原、抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
GB0021617D0 (en) * 2000-09-02 2000-10-18 Imp College Innovations Ltd Diagnosis and treatment of cancer
ATE527375T1 (de) * 2001-04-12 2011-10-15 Imp Innovations Ltd Diagnose und behandlung von brustkrebs mit scn5a
US20060259991A1 (en) * 2003-02-04 2006-11-16 Evotech Neurosciences Gmbh Diagnostic and therapeutic use of scn2b protein for neurodegeneraative diseases
WO2006068822A1 (en) * 2004-12-20 2006-06-29 Genentech, Inc. Notch receptor agonists and uses
JP2009516514A (ja) * 2005-11-21 2009-04-23 ジェネンテック・インコーポレーテッド 新規遺伝子破壊、それらに関する組成物および方法
US8563695B2 (en) * 2007-11-19 2013-10-22 Genentech, Inc. Antibodies that bind β2

Also Published As

Publication number Publication date
US8563695B2 (en) 2013-10-22
JP5745272B2 (ja) 2015-07-08
EP2220123A1 (en) 2010-08-25
JP2011504503A (ja) 2011-02-10
CA2702462A1 (en) 2009-05-28
AU2008326497B2 (en) 2014-02-13
US20110182886A1 (en) 2011-07-28
KR20100087330A (ko) 2010-08-04
JP2015096502A (ja) 2015-05-21
IL204945A0 (en) 2010-11-30
CN101932605A (zh) 2010-12-29
AU2008326497A1 (en) 2009-05-28
BRPI0817393A2 (pt) 2015-03-31
CN101932605B (zh) 2014-06-11
WO2009067429A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
MY184101A (en) Indoles
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
WO2011146879A3 (en) Methods and compositions related to modulating autophagy
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2007123892A3 (en) Raf inhibitors and their uses
EA201390756A1 (ru) Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2009064590A3 (en) Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
MX375221B (es) Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer.
WO2010003520A3 (en) Anti-tumor immunotherapy
MY168762A (en) Certain chemical entities, compositions and methods
WO2014018563A3 (en) Methods for the treatment of cancer
DE602004015811D1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
WO2008089397A3 (en) Adrb2 cancer markers
AU2015314007B2 (en) Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1

Legal Events

Date Code Title Description
FG Grant or registration